Floatz logo

Carboplatin

Bone Metastases

Actuate Therapeutics Inc.Small moleculePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the Bone Metastases cohort.

Asset / SponsorPhaseRating
Zoledronate
Kelly Fitzgerald, MD
Phase 4BBB
Denosumab
Kelly Fitzgerald, MD
Phase 4BBB
Ibandronate
Kelly Fitzgerald, MD
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 3BB
Zometa
Sun Yat-sen University
Phase 4BB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →